Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of face masks on face-to-face neural tracking of speech: Auditory and visual obstacles.

Heliyon·2024
Same author

Author Correction: Epigallocatechin gallate, folic acid, vitamin B12, and hyaluronic acid significantly increase apoptosis and p53 expression in HeLa cells.

European review for medical and pharmacological sciences·2023
Same author

Epigallocatechin gallate, folic acid, vitamin B12, and hyaluronic acid significantly increase apoptosis and p53 expression in HeLa cells.

European review for medical and pharmacological sciences·2023
Same author

The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports.

European review for medical and pharmacological sciences·2021
Same author

Corrigendum to 'Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary' [Gynecologic Oncology 157 (2020) 85-88].

Gynecologic oncology·2021
Same author

Prognostic role of immunohistochemical overexpression of the p16 protein in women under the age of 35 and diagnosed with HSIL (CIN2) subjected to "cervix sparing" excision.

European review for medical and pharmacological sciences·2021

Related Experiment Video

Updated: May 3, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.1K

Gynecologic sarcoma: a clinico-pathological review.

E Ricciardi1, P Maniglio2, R Marziani2

  • 1Department of Obstetrics, Gynecology, and Urology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy. enzo.ricciardi@uniroma1.it

European Journal of Gynaecological Oncology
|January 31, 2014
PubMed
Summary

Accurate diagnosis of uterine sarcomas is crucial, as misdiagnosis can lead to poor patient outcomes. Understanding these rare gynecological tumors is key to improving treatment strategies and clinical practice.

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

22.0K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

25.2K

Related Experiment Videos

Last Updated: May 3, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.1K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

22.0K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

25.2K

Area of Science:

  • Gynecologic Oncology
  • Surgical Pathology
  • Cancer Biology

Background:

  • Uterine sarcomas are rare gynecological malignancies with increasing incidence.
  • Tumors of undetermined malignant potential (UMP) and intermediate features are often misclassified, impacting prognosis.
  • Accurate differentiation between benign and malignant uterine lesions is critical to avoid tragic patient outcomes.

Purpose of the Study:

  • To highlight the diagnostic challenges in uterine sarcomas.
  • To emphasize the importance of understanding the biological behavior of these tumors.
  • To advocate for improved clinical practices in managing uterine sarcomas.

Main Methods:

  • Review of literature on uterine sarcoma classification and prognosis.
  • Analysis of diagnostic criteria for differentiating benign, intermediate, and malignant uterine tumors.
  • Discussion of current therapeutic strategies for uterine sarcomas.

Main Results:

  • Many cases with good prognosis may represent intermediate tumors, not true sarcomas.
  • Misdiagnosis of malignant uterine lesions as benign has severe consequences.
  • Surgery is the primary treatment for sarcomas, with chemotherapy (CTX) and radiation therapy (RT) as adjuvant options.

Conclusions:

  • Enhanced understanding of uterine sarcoma biology is essential for better clinical management.
  • Distinguishing UMP and other intermediate tumors from sarcomas requires refined diagnostic approaches.
  • Early and accurate diagnosis is paramount for effective treatment and improved survival in uterine sarcoma patients.